KOSDAQBiotech & Pharma308430

Cellbion

₩11,340▲ 1.43%2026-11-18 close
Market Cap
₩146.3B
Turnover
₩100M
Volume
9.8K
Shares out.
12.9M
PER
16.9×
PBR
4.3×
EPS
₩721
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Phase 3 Entry for Prostate Cancer RPT, Operating Losses Persist

Cellbion's key variables are the Phase 3 path, conditional approval, and licensing of its prostate cancer radiopharmaceutical Lu-177-DGUL, while operating losses have continued through the disclosed years and the latest five quarters.

  1. 1

    Clinical: The domestic Phase 2 study showed an objective response rate of 35.9%, rising to 47.4% in patients with measurable lesions, and the Phase 3 trial plan was approved in September 2026.

  2. 2

    Approval: The conditional marketing authorization application was filed on December 30, 2025, and review was ongoing as of October 2026, after the company had targeted conditional approval within the first half of 2026.

  3. 3

    Annual results: 2025 revenue was KRW 1.95 billion, operating loss was KRW 8.24 billion, and the operating margin was -423.9%, with losses in each of the three years from 2023.

  4. 4

    Quarterly results: Operating losses ran for five consecutive quarters from Q3 2025 through Q3 2026. The KRW 14.4 billion net profit attributable to controlling shareholders in Q2 2026 came alongside a KRW 2.64 billion operating loss, so it should be read separately from operating results.

  5. 5

    Funding: A third-party allotment rights issue announced in April 2026 was set to raise about KRW 25 billion, of which KRW 17 billion was earmarked for facilities.

02

Business structure

Cellbion is a biotech company developing radiopharmaceutical therapies (RPT), headquartered inside the Cancer Research Institute of Seoul National University. The company listed on KOSDAQ in October 2024 under the technology growth special listing track.

Its core pipeline is Lu-177-DGUL, a PSMA-targeting radiopharmaceutical for metastatic castration-resistant prostate cancer. The domestic Phase 2 study reported an objective response rate of 35.9%, or 47.4% in patients with measurable lesions.

The conditional marketing authorization application was filed on December 30, 2025, and the Phase 3 trial plan (IND) was approved in September 2026. The company has also signed a clinical trial collaboration and supply agreement with Merck (MSD) to evaluate Lu-177-DGUL with Keytruda (pembrolizumab) in a Phase 1 study.

Its stated strategy centers on indication expansion and out-licensing, so licensing deals are the core route to monetization. Novartis's Pluvicto is the reference product in the competitive discussion. Annual revenue of KRW 1.95 billion in 2025 reflects a business still before product approval.

Potential partners are global pharma and biotech companies, and the company said it planned one-on-one partnering meetings with about 19 firms at BIO Japan 2026. A company official said several global pharma firms had reached out first.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩700M-₩2B−294.1%
2025Q4₩400M-₩2.5B−657.6%
2026Q1₩600M-₩2.4B−399.0%
2026Q2₩500M-₩2.6B−559.9%
2026Q3₩500M-₩2.6B−533.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩1.5B-₩5B-₩3.6B−342.8%−48.5%51.3%
2024₩2.3B-₩7.1B-₩7.3B−311.7%−24.6%16.3%
2025₩1.9B-₩8.2B-₩7.6B−423.9%−33.2%54.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue on a disclosed basis rose from KRW 1.47 billion in 2023 to KRW 2.29 billion in 2024 (up 55.6% year on year) and then fell to KRW 1.95 billion in 2025 (down 15.1% year on year), with 2024 the largest year of the three.

Operating losses over the same period were KRW 5.04 billion in 2023, KRW 7.14 billion in 2024 (losses widened), and KRW 8.24 billion in 2025 (losses widened).

In 2024 operating losses grew even as revenue rose, and in 2025 falling revenue and wider losses coincided, which points to revenue not covering the fixed cost base. The operating margin was -342.8% in 2023, -311.7% in 2024, and -423.9% in 2025.

The net loss attributable to controlling shareholders was KRW 3.63 billion in 2023, KRW 7.27 billion in 2024, and KRW 7.57 billion in 2025, and the net loss including non-controlling interests was reported at the same amounts.

At year-end 2025, total equity was KRW 22.8 billion, all attributable to controlling shareholders, total liabilities were KRW 12.4 billion, and the debt ratio was 51.3% in 2023, 16.3% in 2024, and 54.5% in 2025.

Operating cash flow was -KRW 3.94 billion in 2023, -KRW 4.78 billion in 2024, and -KRW 5.55 billion in 2025, so the outflow widened each year.

Quarterly revenue fell from KRW 679 million in Q3 2025 to KRW 382 million in Q4 2025 (down 43.8% quarter on quarter), then rose to KRW 613 million in Q1 2026 (up 60.4%), eased to KRW 472 million in Q2 2026 (down 22.9%), and reached KRW 487 million in Q3 2026 (up 3.1% quarter on quarter, down 28.3% year on year).

Quarterly operating losses ran from KRW 2 billion in Q3 2025 to KRW 2.59 billion in Q3 2026, five consecutive quarters of losses, and the Q3 2026 loss was larger than a year earlier.

Net results attributable to controlling shareholders swung from a loss of KRW 1.83 billion in Q3 2025 to a profit of KRW 14.4 billion in Q2 2026, which turned to a loss of KRW 290 million in Q3 2026.

Because the Q2 2026 profit was far larger than the KRW 2.64 billion operating loss, non-operating items likely drove the gap, so the profit should be read apart from operating results. Net profit attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) totals KRW 9.29 billion.

05

Industry analysis

Radiopharmaceutical therapies attach radioactive isotopes to antibodies or peptides to deliver radiation to tumors. In prostate cancer, an established competitor already leads the global market, so a later entrant must prove differentiation through clinical data.

Media coverage framed Cellbion's Phase 2 results against Novartis's Pluvicto as the reference product. In licensing talks, clinical stage is a key benchmark for technology value, and early-stage talks center on mechanism, early safety, and efficacy potential. Phase 3 candidates carry higher trial and approval costs.

Phase 3 is the stage that confirms real therapeutic value and risk, so Cellbion's negotiating position depends on how quickly Phase 3 data accumulate. The Keytruda combination follows the trend of pairing immunotherapy with radiopharmaceuticals, and its Phase 1 study is ongoing.

A company official cited an industry estimate of more than KRW 1 trillion for the technology value, which is a company-side statement rather than an independent valuation. Media reports suggest that conditional approval could enable an early commercial launch.

Compared with listed Korean biotech peers that rely on licensing and clinical progress, Cellbion has a small revenue base and depends on the value of its development-stage assets. The domestic approval timeline and whether licensing deals close remain the main variables for commercialization.

06

Outlook

The company said it aimed to obtain conditional approval within the first half of 2026 and domestic marketing authorization and patient supply in the second half. As of October 2026, the conditional approval review was still ongoing, so that target timeline had passed.

The Phase 3 trial plan was approved by the Ministry of Food and Drug Safety in September 2026, and subsequent clinical development steps are underway. The Phase 1 study with Merck (MSD) combining Keytruda is also ongoing. On licensing, the company is continuing follow-up talks with some firms it met at BIO Japan 2026.

It also ran a standalone booth at BIO-Europe 2026 to present its pipeline clinical results. Of the April 2026 rights issue proceeds, KRW 17 billion was earmarked for facility investment from 2026 through 2029.

The operating funds include R&D spending such as clinical trial costs, so Phase 3 costs are a major use of the raised capital. Operating losses continued through Q3 2026 on a disclosed basis.

The next checkpoints are the Ministry of Food and Drug Safety's conditional approval decision and whether licensing agreements are disclosed, followed by Phase 3 patient enrollment and operating results in the 2026 annual report.

07

Valuation

PER
16.9×
PBR
4.3×
ROE
30.5%
EPS
₩721
BPS
₩2,827
Dividend per share
₩0

With operating losses continuing, earnings-based multiples are calculated on net profit attributable to controlling shareholders over the last four quarters, which totals KRW 9.29 billion and leans heavily on the single profitable quarter in Q2 2026.

Operating losses ran for five consecutive quarters over the same period, so earnings-based multiples do not fully reflect the operating trend.

Measured against book value, with total equity of KRW 22.8 billion at year-end 2025 all attributable to controlling shareholders, the price-to-book ratio sits in a range of substantial premium to net assets. Dividends are effectively not paid, so dividend yield offers little support for valuation.

From a technology-value perspective, a company official cited an industry estimate above KRW 1 trillion, and that figure comes from the company side. The gap between market value and that estimate is likely to depend on Phase 3 data and the conditional approval outcome. Comparisons with historical valuation bands are limited given large price swings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Clinical data and Phase 3 entry

The Phase 2 study reported an ORR of 35.9%, or 47.4% in patients with measurable lesions, and the Phase 3 trial plan was approved in September 2026. Conditional approval could enable an early launch. Clinical stage is viewed as a key benchmark for technology value in licensing talks.

Expanding global partnering

Cellbion signed a supply and collaboration agreement with Merck (MSD) for a combination Phase 1 study, and planned one-on-one meetings with about 19 firms at BIO Japan 2026. A company official said several global pharma firms had reached out first. The company also ran a standalone booth at BIO-Europe 2026.

Quarterly earnings improvement

Net profit attributable to controlling shareholders turned positive at KRW 14.4 billion in Q2 2026. The Q3 2026 loss of KRW 290 million was smaller than the KRW 1.83 billion loss in Q3 2025. Because the improvement reflects non-operating factors, it should be distinguished from operating improvement.

09

Bear factors

Persistent operating losses

The 2025 operating loss of KRW 8.24 billion was larger than the KRW 5.04 billion in 2023, with an operating margin of -423.9%. Operating losses have run for five consecutive quarters, and the Q3 2026 loss of KRW 2.59 billion was wider than a year earlier. Quarterly revenue has remained in the range of roughly KRW 380 million to KRW 610 million.

Risk of approval timeline slippage

The company had targeted conditional approval within the first half of 2026, but review was still ongoing as of October 2026. Before approval, product sales cannot drive revenue, so the revenue outlook depends on whether licensing deals close. Each delay extends the period of funding needs.

Funding needs and share dilution

A third-party allotment rights issue announced in April 2026 was set to raise about KRW 25 billion, and 762,859 convertible preferred shares were paid in on April 23, 2026. Operating cash outflow widened each year, reaching KRW 5.55 billion in 2025. Repeated fundraising could lead to ongoing dilution for existing shareholders.

10

Risk factors

Clinical outcome risk

Phase 3 is the stage that confirms real therapeutic value and risk, so results could materially change licensing terms and the approval path. Moving from Phase 3 to global approval requires substantial cost and time. Safety results from the combination Phase 1 study are also a variable for later development.

Regulatory timing risk

The conditional approval review began after the December 30, 2025 filing and is still ongoing, while the first-half 2026 target has passed. The outcome and timing will shape the early commercialization outlook. Delays could push back revenue start and affect funding plans.

Licensing and funding risk

Whether overseas licensing deals close remains the main variable for commercialization. If licensing is delayed, development costs must be covered by internal funds, and the company raised about KRW 25 billion through a third-party rights issue in April 2026. Shortfalls could lead to further share issuance.

11

What to watch next

  1. After November 2026 (timing not fixed)

    Ministry of Food and Drug Safety decision on the conditional marketing authorization for Lu-177-DGUL. The outcome and timing determine the early commercialization outlook and when revenue could begin.

  2. After November 2026 (timing not fixed)

    Whether licensing or co-development agreements are signed. Follow-up talks after BIO Japan 2026 and BIO-Europe 2026 are a key variable for commercialization.

  3. End of March 2027 (2026 annual report filing deadline)

    Annual revenue, operating loss, operating cash flow, and debt ratio in the 2026 annual report. This checkpoint shows whether operating losses persist on an annual basis and how funding needs are trending.

  4. Mid-May 2027 (Q1 2027 quarterly report filing deadline)

    The gap between operating results and net profit attributable to controlling shareholders in Q1 2027. It shows whether non-operating items again drive net results, as they did in Q2 2026.

12

Overall view

Cellbion has built Phase 2 clinical data around its prostate cancer radiopharmaceutical Lu-177-DGUL, and the Phase 3 trial plan approved in September 2026 moves development to the next stage.

On a disclosed basis, operating losses widened from 2023 through 2025 and have continued for five consecutive quarters from Q3 2025 through Q3 2026.

The KRW 14.4 billion net profit attributable to controlling shareholders in Q2 2026 appears driven by non-operating items that far exceeded the operating loss, so it should be read apart from operating results.

The conditional approval target of the first half of 2026 has passed, and as of October 2026 review was ongoing, while whether licensing deals close remains a key variable.

Strengths include clinical data, Phase 3 entry, and partnering activity, while weaknesses include persistent operating losses, uncertain approval timing, and dilution from rights issues.

The next checkpoints are the conditional approval decision and licensing disclosures, followed by operating results in the 2026 annual report and Phase 3 progress.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. newspim.com
  2. newsway.co.kr
  3. kr.investing.com
  4. sentv.co.kr
  5. medipana.com
  6. newspim.com
  7. kpanews.co.kr
  8. digitaltoday.co.kr
  9. kpanews.co.kr
  10. m.news.nate.com
  11. news.mt.co.kr
  12. pharm.edaily.co.kr
  13. thebionews.net
  14. v.daum.net
  15. pharm.edaily.co.kr
  16. newsvalue.kr
  17. kr.investing.com
  18. alphabiz.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis